Germany Biosurgery Market Overview, 2031

Key Insights

• The Germany biosurgery market represents the largest and most established national market for surgical biomaterials in Europe. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.The Germany biosurgery market is distinguished by its advanced healthcare infrastructure, high volume of surgical procedures, and the presence of key global and domestic market players. According to the German Federal Statistical Office (Destatis), 16,531,491 surgical procedures were performed on full inpatient hospital patients in 2023. Healthcare expenditure in Germany reached EUR 579.5 billion in 2025, representing a substantial share of GDP, providing significant financial resources to support surgical activity and biosurgical product utilization. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models.
• Germany represents the largest national biosurgery market in Europe, reflecting the country's unparalleled surgical volume, advanced healthcare infrastructure, and presence of key market players. 16,531,491 surgical procedures were performed on full inpatient hospital patients in 2023.Bone-Graft Substitutes represent the largest product category within the German biosurgery market, driven by the high volume of joint replacement procedures. According to the German Endoprosthesis Register (EPRD), 410,333 endoprosthetic procedures on hip or knee were performed in 2024, the highest number ever recorded.
• Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive and robotic surgical techniques across German hospitals.Germany's aging population represents a significant long-term demand driver. The 60–79 age group continues to expand as the "baby boomer" generation enters retirement age, increasing the incidence of age-related health issues requiring surgical intervention.
• The regulatory environment, centered on the European Medical Device Regulation (MDR) and the German Federal Institute for Drugs and Medical Devices (BfArM), plays a decisive role in shaping market dynamics. MDR compliance requirements determine product availability, while healthcare policies influence adoption rates across hospital and ambulatory settings.
Market Outlook
• According to the research report, " Germany Biosurgery Market Overview, 2031," published by Bonafide Research, the Germany Biosurgery Market is anticipated to grow at more than 5.35% CAGR from 2026 to 2031. supported by favorable demographic trends, ongoing technological innovation, and expanding surgical volumes across both inpatient and outpatient settings. The market's growth trajectory is intrinsically linked to the broader German healthcare landscape, including healthcare expenditure, technological adoption, and demographic shifts.
• Germany's healthcare expenditure continues to rise significantly, reaching EUR 579.5 billion in 2025. This substantial healthcare investment provides the financial foundation for sustained surgical activity and biosurgical product utilization. In 2022, current health expenditure in Germany amounted to 12.6% of GDP, the highest share of all 27 EU Member States.The aging German population represents the most significant long-term demand driver. As the "baby boomer" generation enters retirement age, the incidence of age-related conditions requiring surgical intervention will increase correspondingly. Destatis reports that Germany has the highest health expenditure in the EU.
• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. Regulatory support and funding for research and development further foster innovation in the German MedTech sector, which is a key driver of biosurgery market growth.

Market Dynamics



Driver: High and Growing Surgical Volumes Across All Specialties
Germany performs approximately 16.5 million surgical procedures annually on inpatient hospital patients, spanning inpatient hospital settings, ambulatory surgical centers, and outpatient clinics. According to the German Endoprosthesis Register (EPRD), 410,333 endoprosthetic procedures on hip or knee were performed in 2024 the highest number ever recorded, with 199,052 primary hip implantations and 173,252 primary knee implantations. From 2022 to 2024, the number of annual documented hip procedures increased by 18,237 and knee procedures by 36,413. The breadth and depth of surgical activity in Germany ensure that biosurgical products particularly hemostatic agents and sealants are utilized in virtually every operating room. Healthcare expenditure of EUR 579.5 billion (12.4% of GDP) provides the financial infrastructure to support expanding surgical volumes. The continued expansion of surgical capacity, driven by hospital modernization and workforce development, further reinforces this demand driver.

Challenge: Regulatory Complexity and Pricing Pressure
Despite the market's size and sophistication, biosurgery manufacturers face persistent challenges from regulatory complexity and pricing pressure. The European Medical Device Regulation (MDR) , which became fully applicable in 2021 with the transition period ending in 2024, has significantly increased compliance costs and extended time-to-market for new products. The MDR requires more rigorous clinical evidence, stricter post-market surveillance, and enhanced transparency requirements, creating barriers for both established players and emerging competitors. Additionally, Germany's statutory health insurance (SHI) system, which covers the majority of the population, exerts significant pricing pressure through centralized negotiations and reference pricing mechanisms. The Federal Joint Committee (G-BA) determines which medical services and products are reimbursed, and its decisions directly influence adoption rates. The number of hospitals is slightly declining due to structural reforms and market consolidation in the healthcare system, further intensifying competition for hospital contracts. Manufacturers must continually demonstrate both clinical efficacy and cost-effectiveness to justify premium pricing in an increasingly cost-conscious healthcare system.

Trend: Accelerating Adoption of Minimally Invasive and Robotic-Assisted Surgery
The German biosurgery market is experiencing a significant trend toward minimally invasive and robotic-assisted surgical techniques. The adoption of robotic surgical systems is expanding across German hospitals, with technologies enabling more complex procedures to be performed with greater precision and reduced patient trauma. This shift toward advanced surgical platforms creates new opportunities for biosurgical products specifically designed for minimally invasive and robotic applications. Surgical sealants and adhesives that can be delivered through small incisions, hemostatic agents optimized for sprayable application, and staple-line reinforcement products compatible with robotic staplers are increasingly in demand. The growing awareness of minimally invasive techniques as a key driver propelling market expansion will continue to shape product development and commercial strategies.

Policies

• The European Medical Device Regulation (MDR) (EU) 2017/745 serves as the core regulatory framework for biosurgical products in Germany. Manufacturers must comply with MDR requirements for clinical evaluation, post-market surveillance, and product labeling.
• The German Federal Institute for Drugs and Medical Devices (BfArM) serves as the competent authority for medical devices in Germany, overseeing the implementation of the MDR and coordinating with notified bodies to ensure product safety and efficacy.
• Notified bodies designated under the MDR conduct conformity assessments for biosurgical products. Manufacturers must engage with these independent organizations to obtain CE marking, which is mandatory for market access in Germany.
• The Federal Joint Committee (G-BA) determines which medical services and products are reimbursed under Germany's statutory health insurance system, directly influencing adoption rates of biosurgical products.
• Statutory health insurance (SHI) covers the majority of the German population through numerous insurance providers. Statutory health insurance expenditure reached EUR 324.5 billion in 2025.

Segment Analysis

Germany Biosurgery Market By Product • Bone-Graft Substitutes represent the largest product category within the German biosurgery market, driven by the high volume of joint replacement and spinal fusion procedures. The German Endoprosthesis Register (EPRD) reports 410,333 endoprosthetic procedures in 2024, the highest number ever recorded. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. The aging German population continues to drive demand for musculoskeletal interventions requiring bone-graft substitutes.

• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. The increasing volume of surgeries and growing demand for effective hemostatic solutions contribute to the strength of this segment.
• Surgical Sealants and Adhesives represent the fastest-growing product category in the German biosurgery market, driven by increasing adoption of minimally invasive and robotic surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The growing demand for advanced surgical technologies supports the expansion of this segment.
• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention, particularly as the volume of gynecological and abdominal procedures remains substantial.
• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes in German hospitals.
• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines, reducing the risk of bleeding and leakage. The increasing volume of thoracic and gastrointestinal procedures supports steady demand for these products.

Germany Biosurgery Market By Application • Orthopedic Surgery is the largest application area for biosurgical products in Germany, driven by the high volume of joint replacement procedures. The EPRD's record of 410,333 endoprosthetic procedures in 2024 reflects the sustained growth in this specialty. Hip implantations reached 199,052 primary procedures and knee implantations reached 173,252 primary procedures.
• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including bariatric surgery, colorectal surgery, and hernia repair. Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers. Approximately 16.5 million surgical procedures are performed annually in Germany.
• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures. The aging population and increasing incidence of neurological conditions drive demand in this specialty.
• Cardiovascular Surgery represents the fastest-growing application area in the German biosurgery market, driven by the high prevalence of cardiovascular disease in the aging population. Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures.
• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery. The growing volume of trauma and oncological procedures supports demand in this application.
• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement. In 2024, 215,900 cesarean sections were performed in German hospitals.
• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications. The aging male population drives demand for urological interventions.
• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions. Access to the lumbar spine procedures reached 346,903 procedures.

Germany Biosurgery Market By Source/Origin • Biologic products represent the largest source category in the German biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. The MDR's rigorous requirements for biological materials ensure high safety standards and support market confidence.
• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the German market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The SHI system's emphasis on cost-effectiveness favors synthetic alternatives for certain applications.

Germany Biosurgery Market By End-User • Hospitals remain the largest end-user segment for biosurgical products in Germany, accounting for the majority of revenue. Hospitals account for a significant share of healthcare expenditure, reflecting their central role in surgical care delivery. Approximately 16.5 million inpatient surgical procedures are performed in German hospitals annually. The concentration of complex surgical procedures and availability of specialized surgical teams make hospitals the primary setting for biosurgical product utilization.
• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the German biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity supports the adoption of biosurgical products in these settings. This shift is reshaping product portfolios and distribution strategies for biosurgery manufacturers.
• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.

Germany Biosurgery Market Economics

• Germany’s biosurgery market operates within a sophisticated healthcare system characterized by universal coverage and extensive statutory health insurance (SHI). SHI expenditure reached EUR 324.5 billion in 2025, while total healthcare expenditure was EUR 579.5 billion, equivalent to 12.4% of GDP. Pricing remains competitive because reimbursement and purchasing decisions strongly influence product adoption. The Federal Joint Committee (G-BA) determines reimbursable services, while IQWiG conducts health technology assessments. Manufacturers therefore need strong clinical evidence, demonstrated efficacy, and cost-effectiveness to achieve favorable reimbursement and market access.
• Procurement combines hospital-level agreements, group purchasing organizations, and individual surgeon preferences, while ongoing hospital consolidation is increasing competitive pricing pressure, particularly for commoditized biosurgical products. Although the number of hospitals is gradually declining because of structural reforms and market consolidation, Germany retains extensive hospital infrastructure, ambulatory surgical centers, and specialty clinics supporting high surgical volumes. Its well-developed supply chain and central European position also make the country an important manufacturing and distribution hub. Companies such as B. Braun demonstrate Germany’s strong domestic manufacturing capabilities and industrial base.
• Germany’s healthcare infrastructure is supported by a large, highly trained surgical workforce spanning general surgery, orthopedics, neurosurgery, cardiovascular surgery, and other specialties. Academic medical centers and professional organizations contribute to surgical education, quality improvement, and evidence-based practice, supporting adoption of advanced biosurgical technologies. The country also attracts substantial innovation investment because of its strong intellectual property protections, research institutions, teaching hospitals, and established industry-academic collaborations. These capabilities encourage development of advanced biomaterials and products designed for evolving surgical procedures and specialized clinical requirements.
• The regulatory environment is governed primarily by the European Medical Device Regulation (MDR), with BfArM playing an important role in implementation and oversight alongside notified bodies. Germany is also a major adopter of robotic-assisted surgery, minimally invasive procedures, and advanced biomaterials, creating opportunities for specialized biosurgical products. Long-term growth is supported by demographic aging, including the retirement of the baby-boomer generation, which is expected to sustain demand for surgical interventions. Strong healthcare spending, infrastructure, innovation, and technology adoption provide a solid foundation for continued market expansion.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Biosurgery Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Bone-Graft Substitutes
• Hemostatic Agents
• Surgical Sealants & Adhesives
• Adhesion Barriers
• Soft-Tissue Attachments
• Staple-Line Reinforcement

By Application:
• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery
• Urological Surgery
• Other surgeries (Thoracic surgeries & more)

By Source/Origin
• Biologic
• Synthetic / Semi-synthetic

By End-user:
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Others